drugset / Trial / NCT02067910

Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome

NCT02067910

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Sjögren's syndrome (pSS) is a common chronic auto-immune disease, characterised by inflammation of the exocrine glands, resulting in progressive dryness of the eyes and the mouth. Furthermore, many patients experience extraglandular symptoms such as restricting fatigue. Currently, biological agents have been introduced in various systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. No biological agent has yet been approved for the treatment of pSS. In an open-label study, we have shown that abatacept treatment of pSS patients has promising results (Meiners et al., 2014). Therefore, the aim of this study is to evaluate efficacy and safety of subcutaneous abatacept treatment in pSS in a larger and randomized clinical trial.

Timeline

Start
2014-08
Primary completion
2019-02
Completion
2019-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified 125 mg Subcutaneous

Indications